Arbutus Biopharma Corp
(FRA:I9DN)
€
4.3
+0.10 (+2.38%)
Market Cap: 895.93 Mil
Enterprise Value: 812.86 Mil
PE Ratio: 6.22
PB Ratio: 3.91
GF Score: 53/100 Arbutus Biopharma Corp at JMP Securities Life Sciences Conference Transcript
May 16, 2023 / 01:00PM GMT
Release Date Price:
€2.3
Roy Buchanan
JMP Securities - Analyst
Happy to kick it off with Arbutus Biopharma here today. They have the whole team with us here. Bill Collier is President and CEO; Mike Sofia, Chief Scientific Officer; and Dave Hastings, Chief Financial Officer. So thanks for joining us, everyone.
Bill Collier
Arbutus Biopharma Corporation - President, CEO, & Director
Thank you.
Dave Hastings
Arbutus Biopharma Corporation - CFO
Thanks, Roy.
Mike Sofia
Arbutus Biopharma Corporation - Chief Scientific Officer
Thanks.
Roy Buchanan
JMP Securities - Analyst
Glad you guys could be here. So pretty exciting year coming up. You guys are developing, obviously, treatments for chronic hepatitis B, trying to get to a functional cure, also coronavirus therapeutics.
Questions & Answers
Roy Buchanan
JMP Securities - Analyst
So let's start off with the chronic hepatitis B. You've got a
Already have an account? Log in
Get the full story
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |

30-Day 100% money back guarantee
Subscription fee may be tax deductible.
Excellent 

4.6 out of 5
Trustpilot